Click to see our news releases about special projects and other announcements.Read More
Journalists: We are at your service. Please contact us with your request.Connect
Dr. David Sinclair, a Harvard Medical School professor and New York Times bestselling author, was the guest of honor for the ISB-Town Hall Science Series on Thursday. He joined genomics pioneer and ISB Co-founder Dr. Lee Hood for a conversation that covered the very latest in aging research.
In ISB’s first-ever Research Roundtable event, Assistant Professor Dr. Sean Gibbons delivered a presentation titled “Gut-Check: Personalized Nutrition and Your Microbiome.” His talk covered a lot of ground, including recently published research showing how the health of our microbiomes can predict longevity, and how we can build and maintain a healthy gut microbiome.
To advance research at the intersection of COVID-19 and cancer, The Andy Hill CARE Fund has awarded ISB Assistant Professor Dr. Wei Wei a $100,000 grant to study chronic lymphocytic leukemia (CLL), one of the most commonly diagnosed leukemias in the Western world that mainly affects older individuals.
Daniel Chen, an undergraduate researcher in ISB’s Heath Lab and junior at the University of Washington, has been awarded a prestigious Goldwater Scholarship. Chen has been a key member of ISB’s COVID-19 Immune Response Study.
Dr. Naeha Subramanian – an expert in immunology, innate immunity, and host-pathogen interactions, and head of ISB’s Subramanian Lab – has been promoted to Associate Professor. “I am honored with this promotion and excited about the incredible research being conducted in my lab. It is a pleasure and privilege to tackle exciting questions everyday,” she said.
ISB’s research into the aging microbiome was featured in a story published by Anahad O’Connor for The New York Times titled “A Changing Gut Microbiome May Predict How Well You Age.” The research featured was published in Nature Metabolism by Drs. Tomasz Wilmanksi, Noa Rappaport, Sean Gibbons and Nathan Price.
ISB researchers and their collaborators looked at the electronic health records of nearly 630,000 patients who were tested for SARS-CoV-2, and found stark disparities in COVID-19 outcomes — odds of infection, hospitalization, and in-hospital mortality — between White and non-White minority racial and ethnic groups.
ISB research sheds light on how interspecies interactions arise, evolve and are maintained. The results, published in The ISME Journal, provide a new window to understand the key roles of these interactions in industrial applications, and in the health and disease of humans, animals and plants.
Since October, 50 high school teachers representing several school districts across Washington have participated in a series of ISB workshops. “We quickly realized we were in a unique position to help educators pivot into remote teaching,” said Caroline Kiehle.
Providence President and CEO Dr. Rod Hochman joined ISB President and Professor Dr. Jim Heath for an hour-long conversation hosted by ISB and Town Hall Seattle about how healthcare and science will be different in a post-pandemic world.
NIAID Director Dr. Anthony Fauci sat down for a conversation with ISB’s Dr. Lee Hood. The renowned scientists spoke about the importance of basic research, the extraordinary speed of COVID research, the efficacy of mRNA vaccines on COVID-19, lessons learned from the COVID-19 pandemic, and much more.
ISB researchers have found that a small, persistent increase in the expression of NOD1 could be responsible for higher cancer risks. The research team found that a slight 1.5-fold uptick in NOD1 expression can activate the protein and downstream signaling pathways in a manner similar to vast (30- to 200-fold) overexpression.
CRI iAtlas is a comprehensive web-based resource that allows oncologists and researchers to study and analyze interactions between tumors and the immune microenvironment. The iAtlas team released immuno-oncology modules that allow investigators to access and work with genomics data from trials of treatment with immune-checkpoint inhibitors.
Wait, what day is it? What month is it? This year has been a doozy. The pandemic has fundamentally changed our lives, and at times, has made us feel like we’re in a real-life Groundhog Day. Well, if you’ve found yourself in the last-minute shopping scramble, we’re back with a half dozen solid ideas that we hope will make your gift-giving life easier.
GeekWire published a story spotlighting ISB’s COVID-19 research. Reporter Lisa Stiffler spoke with ISB President Dr. Jim Heath about the breakneck pace ISB and all of our collaborative partners are working at to tease out COVID’s biological secrets to advance the understanding and treatment of the novel coronavirus.
ISB researchers Dr. Nitin Baliga, Dr. Eliza Peterson and Dr. Vivek Srinivas have developed a new cell sorting technology, called PerSort, that isolates and characterizes dormant persisters that exist in cultures of Mycobacterium tuberculosis, the pathogen that causes tuberculosis.